
Katherine Stemke Stemke-Hale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2984637/publications.pdf Version: 2024-02-01



KATHERINE STEMKE

#	Article	IF	CITATIONS
1	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. Cancer Research, 2014, 74, 4845-4852.	0.4	148
2	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2014, 13, 2738-2750.	1.9	72
3	A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer, 2014, 14, 120.	1.1	68
4	Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics, 2013, 7, 11807.	1.2	186
5	Correlations between the dielectric properties and exterior morphology of cells revealed by dielectrophoretic fieldâ€flow fractionation. Electrophoresis, 2013, 34, 1042-1050.	1.3	143
6	Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems. Biomicrofluidics, 2013, 7, 11808.	1.2	101
7	Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Modern Pathology, 2013, 26, 544-552.	2.9	13
8	Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome. PLoS ONE, 2013, 8, e65144.	1.1	50
9	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. Journal of Immunotherapy, 2012, 35, 66-72.	1.2	111
10	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Research, 2012, 22, 2120-2129.	2.4	206
11	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	13.5	2,247
12	Systematic analysis of genotypeâ€specific drug responses in cancer. International Journal of Cancer, 2012, 131, 2456-2464.	2.3	28
13	Detection algorithm for the validation of human cell lines. International Journal of Cancer, 2012, 131, E1024-30.	2.3	13
14	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine, 2012, 18, 1052-1059.	15.2	219
15	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106
16	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology, 2012, 126, 47-53.	0.6	74
17	Interactions between tumor cells and microenvironment in breast cancer: A new opportunity for targeted therapy. Cancer Science, 2012, 103, 400-407.	1.7	18
18	Dynamic physical properties of dissociated tumor cells revealed by dielectrophoretic field-flow fractionation. Integrative Biology (United Kingdom), 2011, 3, 850.	0.6	58

KATHERINE STEMKE

#	Article	IF	CITATIONS
19	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics, 2011, 43, 442-446.	9.4	449
20	<i>ZNF668</i> Functions as a Tumor Suppressor by Regulating p53 Stability and Function in Breast Cancer. Cancer Research, 2011, 71, 6524-6534.	0.4	26
21	Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nature Genetics, 2011, 43, 1119-1126.	9.4	133
22	Incidence and Outcome of <i>BRCA</i> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clinical Cancer Research, 2011, 17, 1082-1089.	3.2	487
23	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2011, 10, 1093-1101.	1.9	204
24	High Frequency of <i>PIK3R1</i> and <i>PIK3R2</i> Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discovery, 2011, 1, 170-185.	7.7	419
25	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell, 2010, 18, 423-435.	7.7	129
26	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Research, 2009, 69, 4116-4124.	0.4	768
27	Activity of dasatinib against <i>L576P KIT</i> mutant melanoma: Molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics, 2009, 8, 2079-2085.	1.9	178
28	Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. Clinical Cancer Research, 2009, 15, 2472-2478.	3.2	185
29	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research, 2009, 15, 3654-3662.	3.2	121
30	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 7538-7546.	3.2	221
31	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. Cancer Cell, 2009, 16, 21-32.	7.7	472
32	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research, 2008, 68, 6084-6091.	0.4	916
33	A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer Cell, 2007, 12, 395-402.	7.7	1,471
34	Molecular screening for breast cancer prevention, early detection, and treatment planning: Combining biomarkers from DNA, RNA, and protein. Current Oncology Reports, 2006, 8, 484-491.	1.8	10
35	Expression Library Immunization: a Road Map for Discovery of Vaccines against Infectious Diseases. Infection and Immunity, 2005, 73, 7089-7098.	1.0	16
36	Screening the whole genome of a pathogen in vivo for individual protective antigens. Vaccine, 2005, 23, 3016-3025.	1.7	32

#	Article	IF	CITATIONS
37	A Library-Selected, Langerhans Cell-Targeting Peptide Enhances an Immune Response. DNA and Cell Biology, 2004, 23, 742-752.	0.9	34
38	Direct Association between the Yeast Rad51 and Rad54 Recombination Proteins. Journal of Biological Chemistry, 1996, 271, 33181-33186.	1.6	153